Phase II trial of ipilimumab monotherapy in melanoma patients with brain metastases.

8523 Background: Ipilimumab (Ipi), a human monoclonal antibody that blocks CTLA-4, has activity in advanced melanoma. We present results from a phase II trial (CA184-042) to assess Ipi safety and a...